HA STEM VACCINE FOR HA ANTIBODY-POSITIVE TARGETS
The present invention relates to vaccines against influenza virus infection or disease for targets with pre-existing antibodies against influenza virus HA head domain. The invention regards a recombinant vector expressing a HA stem polypeptide, a vaccine comprising the vector or a host cell with said vector, uses of the vector, the host cell, or the vaccine, and methods for reducing influenza virus infection or disease. The recombinant vector can be a nucleic acid such as a eukaryotic expression plasmid or an RNA, a virus, or a replicon particle (RP). This vaccination allows for the induction of an early- and effective immune-response against Influenza virus induced infection or disease, not hindered by pre-existing anti-HA head domain antibodies.
1 - 7 . (canceled)
8 . A method for reducing infection or disease caused by an influenza virus in a target that has antibodies against an Influenza virus HA head domain at the time of vaccination, said method comprising administering to said target a vaccine comprising a recombinant vector capable of expressing a recombinant Influenza virus haemagglutinin (HA) stem polypeptide in the target and a pharmaceutically acceptable carrier; wherein said recombinant Influenza virus HA stem polypeptide comprises a headless Influenza virus HA stem domain, a trimerization domain, and a transmembrane domain.
9 . The method of claim 8 , wherein said recombinant Influenza virus HA stem polypeptide has the amino acid sequence selected from one of SEQ ID NO's: 4, 6, 8, 10, and 12.
10 . The method of claim 9 , wherein said recombinant vector is selected from a nucleic acid, a virus, and a replicon particle (RP).
11 . The method of claim 8 , wherein said recombinant vector is selected from a nucleic acid, a virus, and a replicon particle (RP).
12 . The recombinant vector of claim 11 , wherein:
the nucleic acid is a eukaryotic expression plasmid or an RNA molecule;
the virus is selected from a Herpesvirus, a Poxvirus, a Retrovirus, a Paramyxovirus, a Rhabdovirus and an Adenovirus; or
the RP is an Alphavirus RP.
13 . The recombinant vector of claim 10 , wherein:
the nucleic acid is a eukaryotic expression plasmid or an RNA molecule;
the virus is selected from a Herpesvirus, a Poxvirus, a Retrovirus, a Paramyxovirus, a Rhabdovirus and an Adenovirus; or
the RP is an Alphavirus RP.
14 . A method for reducing infection or disease caused by an influenza virus in a target that has antibodies against an Influenza virus HA head domain at the time of vaccination, said method comprising administering to said target a host cell comprising a recombinant vector, said recombinant vector being capable of expressing a recombinant Influenza virus haemagglutinin (HA) stem polypeptide in the target; wherein said recombinant Influenza virus HA stem polypeptide comprises a headless Influenza virus HA stem domain, a trimerization domain, and a transmembrane domain.
15 . The method of claim 14 , wherein said recombinant Influenza virus HA stem polypeptide has the amino acid sequence selected from one of SEQ ID NO's: 4, 6, 8, 10, and 12.
16 . The method of claim 15 , wherein said recombinant vector is selected from a nucleic acid, a virus, and a replicon particle (RP).
17 . The method of claim 14 , wherein said recombinant vector is selected from a nucleic acid, a virus, and a replicon particle (RP).
18 . The recombinant vector of claim 17 , wherein:
the nucleic acid is a eukaryotic expression plasmid or an RNA molecule;
the virus is selected from a Herpesvirus, a Poxvirus, a Retrovirus, a Paramyxovirus, a Rhabdovirus and an Adenovirus; or
the RP is an Alphavirus RP.
19 . The recombinant vector of claim 16 , wherein:
the nucleic acid is a eukaryotic expression plasmid or an RNA molecule;
the virus is selected from a Herpesvirus, a Poxvirus, a Retrovirus, a Paramyxovirus, a Rhabdovirus and an Adenovirus; or
the RP is an Alphavirus RP.